Literature DB >> 9252144

Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver.

K Shimamatsu1, I R Wanless.   

Abstract

Ischemia is known to be a cause of hepatocellular apoptosis and atrophy in experimental animals, but the effect of vascular obstruction on such lesions in the normal or cirrhotic human liver has not been studied. The purpose of this study was to investigate the role of ischemia in the development of apoptosis, atrophy, and nodular hyperplasia in cirrhotic and noncirrhotic human livers. Apoptosis, focal atrophy, and nodular hyperplasia were semiquantitated in 203 liver specimens obtained at transplantation, segmental resection, or autopsy. These parameters were correlated with etiology, stage, activity, and acute and healed portal vein thrombosis (PVT). Large numbers of apoptotic cells were found in livers with acute PVT (17.2/medium-power field [MPF]) and in infarcts of Zahn caused by obstruction of portal veins (PVs) by tumor (16.4/MPF). Smaller numbers of apoptotic cells were found in cirrhosis of various etiologies (3.8-10.0/MPF) and rarely in normal livers (0.16/MPF). Evidence of healed PVT was found in 47% of cirrhotic livers and was associated with nodular hyperplasia (58% vs. 32%, P < .01) and focal atrophy (79% vs. 49%, P < .002). Apoptotic cells were found equally in those with and without healed PVT (40% vs. 38%, not significant). These observations suggest that apoptosis is a transient response to acute ischemia and that atrophy and nodular hyperplasia are chronic responses to ischemia. Vascular obstruction may be an important cause of the apoptosis and atrophy, which are found in nodular regenerative hyperplasia (NRH), infarct of Zahn, chronic hepatitis, and cirrhosis.

Entities:  

Mesh:

Year:  1997        PMID: 9252144     DOI: 10.1002/hep.510260214

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Diminished energy metabolism and enhanced apoptosis in livers of B6C3F1 mice treated with the antihepatocarcinogen rotenone.

Authors:  C Wang; J Youssef; B Saran; P G Rothberg; M L Cunningham; A Molteni; M Badr
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

2.  Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia.

Authors:  O Buchel; T Roskams; B Van Damme; F Nevens; J Pirenne; J Fevery
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Effect of normothermic liver ischemic preconditioning on the expression of apoptosis-regulating genes C-jun and Bcl-XL in rats.

Authors:  Guo-Huang Hu; Xin-Sheng Lu
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

Review 4.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors.

Authors:  Chandrashekhar R Gandhi; Noriko Murase; Vladimir M Subbotin; Tadahiro Uemura; Michael Nalesnik; Anthony J Demetris; John J Fung; Thomas E Starzl
Journal:  J Hepatol       Date:  2002-09       Impact factor: 25.083

6.  Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease.

Authors:  Nicole L Ward; Alexandra L Haninec; Paul Van Slyke; John G Sled; Celina Sturk; R Mark Henkelman; Ian R Wanless; Daniel J Dumont
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Nodular regenerative hyperplasia in common variable immunodeficiency.

Authors:  Ivan J Fuss; Julia Friend; Zhiqiong Yang; Jian Ping He; Lubna Hooda; James Boyer; Liqiang Xi; Mark Raffeld; David E Kleiner; Theo Heller; Warren Strober
Journal:  J Clin Immunol       Date:  2013-02-19       Impact factor: 8.317

Review 8.  Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.

Authors:  Archita Sood; Mariana Castrejón; Sammy Saab
Journal:  World J Hepatol       Date:  2014-01-27

Review 9.  Portal vein thrombosis: should anticoagulation be used?

Authors:  Stephen E Congly; Samuel S Lee
Journal:  Curr Gastroenterol Rep       Date:  2013-02

10.  Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease.

Authors:  Jordan J Feld; Nadeem Hussain; Elizabeth C Wright; David E Kleiner; Jay H Hoofnagle; Sushil Ahlawat; Victoria Anderson; Dianne Hilligoss; John I Gallin; T Jake Liang; Harry L Malech; Steven M Holland; Theo Heller
Journal:  Gastroenterology       Date:  2008-03-04       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.